Prolonged P2Y-receptor signalling can cause vasoconstriction leading to hypertension, vascular smooth muscle hypertrophy, and hyperplasia. G protein-coupled receptor signalling is negatively regulated by G protein-coupled receptor kinases (GRKs) and arrestin proteins, preventing prolonged or inappropriate signalling. This study investigates whether GRKs and arrestins regulate uridine 5 ′ -triphosphate (UTP)-stimulated contractile signalling in adult Wistar rat mesenteric arterial smooth muscle cells (MSMCs).
Introduction
Extracellular nucleotides play important roles in cardiovascular physiology, and in vascular tissues prolonged nucleotide signalling has been implicated in the pathophysiology of restenosis, diabetic microvascular disease, and hypertension. 1 Purine/pyrimidine nucleotide release can have different effects on vascular tone depending on the site of release and cell type(s) with which the nucleotide interacts. 1 Nucleotides released from endothelial cells after shear stress and/or hypoxia can cause smooth muscle relaxation; 1,2 contrastingly, nucleotide release from sympathetic neuronal inputs act directly on vascular smooth muscle causing contraction. 1, 3, 4 Nucleotide signalling is mediated through different classes of receptor, including the ionotropic P2X and metabotropic P2Y receptor families. 5 Vascular smooth muscle cell contractile responses are mediated through the P2X 1 subtype and several P2Y subtypes (i.e. P2Y 2, 4, 6 ). P2X 1 -receptors cause a rapid influx of Ca 2+ to initiate smooth muscle contraction. The G protein-coupled receptors (GPCRs) P2Y 2 , P2Y 4 , and P2Y 6 couple with Ga q/11 proteins to activate phospholipase C (PLC), generating inositol 1,4,5-trisphosphate (IP 3 ) and diacylglycerol. This initiates the mobilization of intracellular Ca 2+ stores, activation of protein kinase C, and induces contraction. 1, 5 Both P2X-and P2Y-mediated pathways are known to contribute significantly to the control of vascular tone. 3, 6, 7 Considering the potentially important roles that P2Y-receptors may play in the aetiology of vascular disease, very little is currently known regarding the regulation of their signalling in vascular smooth muscle. P2Y-receptors, like most GPCRs, are known to undergo desensitization, 8, 9 a process which can prevent prolonged/ inappropriate receptor-mediated signalling. 10 Desensitization of agonist-occupied GPCRs is usually initiated by the recruitment of G protein-coupled receptor kinases (GRKs), which phosphorylate key serine/threonine residues within the third intracellular (i3) loop and/ or C-terminal tail of the GPCR. 10 GRK-mediated phosphorylation promotes the binding of non-visual arrestins (arrestin2 and/or arrestin3), which sterically inhibit GPCR-G protein interactions, and promote receptor internalization. 10, 11 Of the seven GRK isoenzymes (GRK1 -7) and four arrestin isoforms (arrestin1 -4) expressed in mammals, GRK2, GRK3, GRK5, and GRK6, and arrestin2 (b-arrestin-1) and arrestin3 (b-arrestin-2) are commonly reported to be ubiquitously expressed. 10 Here, we have characterized the desensitization and resensitization of P2Y-receptor responses in mesenteric arterial smooth muscle cells (MSMCs), a widely documented model of systemic resistance arteries. 12 Furthermore, we have combined confocal imaging with biochemical and molecular biological manipulation of individual GRK and arrestin subtypes to identify their roles in the regulation of endogenous P2Y-receptor-stimulated PLC signalling and contraction of MSMCs.
Methods

Isolation and culture of MSMCs
Adult male Wistar rats were killed by cervical dislocation, a method approved under the United Kingdom Animals (Scientific Procedures) Act 1986. The investigation also conforms to the Guide for Care and Use of Laboratory Animals US (NIH Publication No. 85-23, revised 1996). Smooth muscle cells were isolated from small branches of mesenteric artery by enzymatic dissociation as previously described. 12 Smooth muscle cells were separated by gentle trituration in 231 medium (Cascade Biologics, Nottingham, UK), supplemented with smooth muscle growth supplement, 100 IU/mL penicillin, 100 mg/mL streptomycin, and 2.5 mg/mL amphotericin B. Cells plated onto coverslips were maintained at 378C and 5% CO 2 in humidified conditions.
Myography
Contractile force recordings were made from 2 to 4 mm ring segments of third-order mesenteric arteries mounted in a Mulvany-Halpern wire myograph (JP Trading, Denmark). The bath solution contained (mM): NaCl 134, KCl 6, MgCl 2 1, CaCl 2 1.8, glucose 4, mannitol 6, HEPES 10, pH 7.4. NaCl was reduced to 81 mM and replaced with 60 mM K + for the high K + solution. All bathing solutions contained L-NAME (20 mM) to prevent endogenous nitric oxide production. Solutions and drugs were added directly to the organ bath, maintained at 378C. 
Single cell confocal imaging
UTP-stimulated PLC activity was determined in MSMCs transfected (24 -48 h after isolation) with the pleckstrin-homology domain of phospholipase Cd1 tagged with enhanced green fluorescent protein (eGFP-PH, 0.5 mg an extensively characterized IP 3 biosensor 13 ) using confocal imaging exactly as previously described 14 (see Supplementary material online). Changes in cytosolic eGFP-PH fluorescence are displayed as the fluorescence emission (F )/initial basal fluorescence (F 0 ) (F/F 0 ). Additional Ca 2+ experiments in the absence of eGFP-PH were conducted using Fluo-4-AM (3 mM, 60 min) and imaged as for eGFP.
Manipulating cellular GRK and arrestin levels
To assess the role that GRKs play in the regulation of P2Y-receptor signalling, MSMCs were co-transfected with eGFP-PH (0. ′ ; 100 nM), or NC siRNA (100 nM) (Applied Biosystems, UK). Arrestin depletion was assessed 48 h after nucleofection (Lonza AG, Cologne, Germany) by immunoblotting using an anti-arrestin2 antibody (A1CT). Arrestin expression was quantified using the GeneGnome image analysis system (Syngene, Cambridge, UK). For signalling studies, MSMCs were transfected using Lipofectamine2000 (Invitrogen, Paisley, UK) according to manufacturer's instructions and PLC activity assessed as described above.
Manipulating cellular P2Y receptor levels
An siRNA approach was also applied to delineate the respective roles of P2Y 2 -and P2Y 4 
Data and statistical analysis
Data presented are from cells obtained from at least three separate preparations, expressed as means + SEM. Data were analysed using one-way G.E. Morris et al.
ANOVA as indicated, with appropriate post hoc testing (GraphPad Prism, San Diego, CA, USA).
Results
Characterization of UTP-mediated contractions in mesenteric arteries
Concentration-dependent contractions of third-order mesenteric arteries ( Figure 1A and B) were induced by UTP addition, with maximal contraction seen at UTP concentrations ≥50 mM (EC 50 28 mM). Repeated addition of maximal UTP (100 mM, 5 min) concentrations, interspersed by 5 min wash periods produced robust arterial contractions with little evidence of tachyphylaxis (data not shown). These findings are consistent with those previously obtained for H 1 histamine receptor-mediated Ca 2+ responses, 15 where desensitization is masked by the presence of significant cell/tissue receptor reserve with respect to the observed response. To uncover any potential loss of UTP-induced contractile responsiveness, an amended protocol was applied where arteries were challenged with an approximate EC 50 concentration of UTP (30 mM) for 5 min before (R 1 ) and after (R 2 ) the addition of a maximal UTP GRK2 and arrestin2 regulate UTP-mediated arterial contraction concentration (R max ¼ 100 mM, 5 min). Arteries were washed for 5 min between R 1 and R max , and for 2-15 min between R max and R 2 agonist challenges. Reduced R 2 /R 1 ratios are interpreted as an index of receptor/tissue desensitization. 14,15 R 2 contractile responses compared with R 1 were dramatically reduced (by 80%) following R max exposure when the inter-R max /R 2 delay was 2 min ( Figure 1E ); extending the inter-R max /R 2 wash period revealed a time-dependent resensitization of UTP-induced contractions with the R 1 /R 2 ratio returning to 1 after 12 -15 min ( Figure 1C -E).
3. Figure S1C ).
Since our data suggested that MSMCs express a mixed P2Y 2 / P2Y 4 -receptor population, we applied an siRNA approach specifically to deplete the expression of these P2Y-receptor subtypes individually. The effectiveness of siRNA constructs to suppress P2Y 2 -and P2Y 4 -receptor mRNAs was determined using real-time reverse transcription-polymerase chain reactions (RT-PCR) (see Section 2.6) in rat aortic smooth muscle cells 48 h after nucleofection with siRNA constructs targeting P2Y 2 -or P2Y 4 -receptor mRNAs or a NC (non-targeting) siRNA. Data show that nucleofection with NC siRNA had no effect on P2Y 2 or P2Y 4 signals (data not shown), while in the presence of anti-P2Y 2 siRNA, mean P2Y 2 cycle threshold values were suppressed (DC T ¼ 22.0, relative to NC siRNA-transfected samples), with no effect on the P2Y 4 signal (Figure 2A) . Conversely, anti-P2Y 4 siRNA suppressed mean cycle threshold values for P2Y 4 (DC T ¼ 23.4), but was without effect on P2Y 2 signals. Neither P2Y-targeting siRNA altered b-actin mRNA levels significantly (data not shown). Collectively, these data suggest that ≥75% and ≥90% P2Y mRNA transcripts are selectively depleted following transfection of rat vascular smooth muscle with anti-P2Y 2 or anti-P2Y 4 siRNAs, respectively. The contributions P2Y 2 -and P2Y 4 -receptors play in UTP-mediated PLC signalling were determined in MSMCs co-transfected with eGFP-PH and NC, anti-P2Y 2 or anti-P2Y 4 siRNAs. NC siRNA nucleofection had no significant effect on the magnitude and profile of UTP-stimulated responses in MSMCs (data not shown). UTP-induced eGFP-PH translocation was virtually ablated in MSMCs treated with anti-P2Y 2 siRNA, whereas anti-P2Y 4 siRNA treatment was without effect ( Figure 2C-E) . Furthermore, responses to endothelin-1 were also unaltered following P2Y 2 -depletion ( Figure 2C) . Collectively, these data strongly suggest that in cultured MSMCs, UTP-mediated signalling via PLC is mediated primarily and perhaps exclusively by P2Y 2 -receptors.
Desensitization and resensitization of UTP-signalling in isolated MSMC
Time-courses of desensitization/resensitization of receptor -PLC signalling in response to UTP were assessed using similar protocols as those described above for myography experiments, however shorter agonist applications at lower concentrations (R 1 /R 2 10 mM UTP, 30 s; R max 100 mM UTP, 30 s) were sufficient to induce significant desensitization (Figure 3) Figure 3E ).
GRK isoenzymic dependency of P2Y-receptor desensitization in MSMCs
To determine whether endogenous GRKs regulate UTP signalling in MSMCs, individual GRK isoenzymes were inhibited using catalytically inactive, dominant-negative mutant GRKs. MSMCs were co-transfected with eGFP-PH (0.5 mg) together with pcDNA3 (control), GRK6 displayed similar reductions in R 2 responses ( 70%) compared with R 1 , comparable to responses observed in non-transfected cells (Figure 4) . However, the presence of D110A,K220R GRK2 significantly attenuated reductions in the R 2 response when compared with R 1 ( Figure 4B and F), suggesting that endogenous GRK2 activity plays a significant role in regulating UTP-stimulated P2Y-receptor-mediated PLC/Ca 2+ signalling.
To corroborate these findings, we applied a previously validated siRNA that specifically depletes endogenous GRK2 (by ≥75%) without altering the expression of non-targeted GRKs.
14 MSMCs were co-transfected with eGFP-PH (0.5 mg) and either 10 nM anti-GRK2 or NC siRNAs and 48 h later subjected to the standard R 1 /R max /R 2 desensitization protocol ( Figure 5A and B). In agreement with our data from D110A,K220R
GRK2 co-transfections, siRNA-induced depletion of GRK2 attenuated the decrease in R 2 (relative to R 1 ) caused by R max UTP-addition ( Figure 5B and C) . This was most striking for the eGFP-PH/IP 3 response (R 2 /R 1 (%), negative control siRNA, 32 + 8; anti-GRK2 siRNA, 71 + 7; P , 0.05; data are means + SEM). Taken together, these findings strongly suggest that GRK2 is a key mediator of UTP-induced P2Y 2 receptor desensitization.
Arrestin dependency of P2Y 2 -receptor desensitization in MSMCs
To examine the potential role that arrestin proteins play in regulating P2Y 2 -receptor signalling, we utilized an siRNA approach to selectively deplete endogenous arrestin2/3 expression. MSMCs were transfected with anti-arrestin2, anti-arrestin3, or NC siRNAs (100 nM) 48 h prior to cell lysis and immunoblotting. Substantial arrestin depletion (.70% for arrestin2 and arrestin3) was observed at this time-point, and both arrestin2-and arrestin3-targeted siRNAs appeared to be highly selective for their respective targets ( Figure 6A and B) . To determine the effects of arrestin depletion on the desensitization of UTP-stimulated PLC signalling, MSMCs were co-transfected with eGFP-PH (0.5 mg) and anti-arrestin2 or anti-arrestin3, before being subjected to the standard R 1 /R max /R 2 desensitization protocol. In the absence or presence of NC siRNA reductions in R 2 relative to R 1 responses of ≥80% for eGFP-PH and ≥70% for [Ca 2+ ] i signals were observed ( Figure 6C and E).
Selective depletion of arrestin2 markedly reversed UTP-induced decreases in R 2 relative to R 1 IP 3 /Ca 2+ responses ( Figure 6E) . Contrastingly, while arrestin3 depletion had a small effect on R 2 /R 1 ratios ( Figure 6E ), this did not achieve statistical significance, suggesting that attenuation of the UTP signal is primarily effected by the arrestin2 isoform. Previously we showed that GRK2 regulates endothelin (ET A ) receptor desensitization, 14 suggesting that ET A Rs are also likely substrates for arrestin recruitment in MSMCs. Consequently, the potential involvement of arrestin proteins in the regulation of ET A receptor signalling was assessed in MSMCs co-transfected with eGFP-PH and either anti-arrestin2 or anti-arrestin3 siRNAs. Here, ET A receptor desensitization was assessed by exposing cells to a short desensitizing pulse of endothelin-1 (50 nM, 30 s, termed R 1 ) followed by a 10 min wash period and second endothelin-1 challenge (50 nM, 30 s, termed R 2 ). The extent of receptor desensitization, assessed at the level of IP 3 GRK2 and arrestin2 regulate UTP-mediated arterial contraction GRK2 and arrestin2 regulate UTP-mediated arterial contraction or Ca 2+ , was similar in the absence or presence of NC, or antiarrestin2 siRNAs ( Figure 6F and H) , whereas, in anti-arrestin3 siRNAtransfected MSMCs endothelin-1-induced receptor desensitization was significantly attenuated ( Figure 6G and H). These data suggest while both P2Y 2 -and ET A -receptors are desensitized via a GRK2-dependent mechanism in MSMCs, it is likely that different arrestins are recruited to the desensitized receptor, with P2Y 2 -and ET A -receptors preferentially recruiting arrestin2 and arrestin3, respectively.
Discussion
The relative importance of different P2 receptor subtypes present in smooth muscle for contraction is complex and delineation of the contributions of specific subtypes complicated by the lack of highly selective agonists/antagonists. Available data suggest that G proteincoupled P2Y 2 , P2Y 4 , and P2Y 6 receptors, and ionotropic P2X 1 receptors contribute to nucleotide-mediated contraction. 4, 16 Furthermore, evidence from aortic smooth muscle cells suggests that P2Y-receptor mRNA abundance differs between contractile and synthetic phenotypes, with decreases in P2Y 4 /P2Y 6 , and increases in P2Y 2 mRNA being observed in the synthetic phenotype. 17 Our pharmacological and siRNA knockdown data indicate that UTP/PLC responses in isolated MSMCs are primarily mediated by P2Y 2 receptors, which concurs with previous findings that UTP-mediated contractions in mesenteric arteries (.180 mm) are sensitive to blockade by the P2Y 2 -selective antagonist suramin. 16 Furthermore, our UTPstimulated arterial contractile (EC 50 28 mM) and MSMC Ca 2+ (EC 50 6 mM) responses are comparable to those reported in small (.100 mm) mesenteric arteries. 16 Previous studies have described desensitization of P2Y 2 -receptor responses in several cell backgrounds, 8, 9, 18, 19 however, few studies have addressed the regulation of native P2Y 2 -receptor responsiveness and none to our knowledge have done so in mesenteric arteries. In human promonocytic U937, astrocytoma 132N1 and epithelial HT-29 cells P2Y 2 -receptor desensitization has been reported to occur rapidly and is enhanced following phorbol ester addition, however in all cases inclusion of PKC inhibitors failed to prevent receptor desensitization. 9, 18 Indeed, the observed attenuations of signalling may have been the result of PKC-mediated inhibition of PLC activity. 20 Interestingly, protein phosphatase inhibitors can attenuate P2Y 2 -receptor resensitization. 18 Collectively, these findings suggest that P2Y 2 -receptor phosphorylation, by a kinase(s) other than PKC is required for desensitization. 18 Our preliminary experiments demonstrated that a protocol similar to that utilized to study H 1 histamine-receptor desensitization allows quantitative assessment of the desensitization of MSMC responses to UTP. 15 By employing a protocol where a sub-maximally effective ( EC 50 ) concentration of agonist is added to cells before (R 1 ) and after (R 2 ) a maximal, desensitizing agonist exposure (R max ), attenuations of responsiveness are detected irrespective of P2Y 2 -receptor reserve. Moreover, we have extended this approach and utilized a similar R 1 /R max /R 2 protocol in small, intact mesenteric vessels ( 150 mm diameter) to assess receptor desensitization/resensitization at the level of the UTP-evoked contractile response. Interestingly, our data indicate that UTP-stimulated GRK2 and arrestin2 regulate UTP-mediated arterial contraction intact vessel contractions are relatively resistant to desensitization when compared with PLC/Ca 2+ responses in primary MSMCs.
These differences might relate to the differing capacities of intact mesenteric smooth muscle and cultured MSMC preparations to metabolize UTP, and/or ex vivo changes in receptor populations and/or post-receptor components. Nevertheless, using comparable protocols, it is possible to assess the time-course of receptor desensitization/resensitization with respect to both UTP-stimulated contractile and signalling responses in tissue/cell preparations. Since GRK proteins are known to regulate the signalling of other PLC-coupled GPCRs expressed in MSMCs, 14, 21, 22 we initially utilized dominant-negative (kinase-dead) GRK mutants to disrupt P2Y 2 -receptor/GRK isoenzyme-specific interactions in an attempt to attenuate or prevent the reduction in receptor responsiveness observed on re-addition of UTP subsequent to a desensitizing pulse of this agonist. The D110A,K220R
GRK2 construct, which has been mutated to prevent both kinase activity and Ga q/11 -binding, 20 markedly attenuated P2Y 2 -receptor desensitization. Conversely, overexpression of D110A,K220R GRK3, K215R GRK5, or K215R GRK6 mutants affected neither the extent of desensitization, nor the time-course of recovery of P2Y 2 -receptor responsiveness to UTP. To complement our findings (and address any potential criticisms associated with the recombinant over-expression of GRK mutants), we also depleted (.75%) endogenous GRK2 expression in MSMCs using isoenzymespecific siRNAs, producing near-identical data to those obtained using the D110A,K220R GRK2 construct.
Together these findings indicate that GRK2 is a key endogenous GRK isoenzyme initiating P2Y 2 -receptor desensitization in MSMCs, with either GRK2 knockdown or disruption of the normal GRK2-receptor interaction causing an 60% attenuation of agoniststimulated P2Y 2 -receptor desensitization; a figure only 15% less than that achievable after full receptor resensitization. It is possible that GRK2 is the only kinase involved in initiating P2Y 2 -receptor desensitization and that the observed partial effects arise because the experimental ablations of GRK2 activity are incompletely effective. On the other hand, while a predominant GRK isoenzyme can often be identified as being responsible for initiating receptor desensitization it is rare for this to be the only protein kinase involved. 23, 24 Therefore, other (minor) mechanisms may yet be shown to be involved in regulating P2Y 2 -receptor responsiveness in MSMCs. GRK2 has previously been reported to be the key GRK isoenzyme regulating angiotensin II type 1 (AT 1 ), 25 a 1D -adrenergic, 22 and ET A 14 receptor-mediated contractile responses. The finding that GRK2 is also key to the regulation of P2Y 2 -receptor signalling further emphasizes the importance of this GRK isoenzyme in Ga q/11 /PLC-coupled receptor regulation in arterial smooth muscle. GRK-mediated phosphorylation often leads to arrestin recruitment to the receptor, promoting internalization, receptor recycling, and/or downregulation. 10, 11 When expressed in HEK293 cells, P2Y 2 -receptors recruit both exogenous arrestin2 and arrestin3, 26 however, while suggestive that P2Y 2 receptors can interact with arrestin proteins, these studies are not necessarily predictive of how, or if, these receptors are regulated in native tissues. Here, we utilized an RNAi strategy to suppress individual arrestin isoform expression to delineate for the first time their role in P2Y 2 receptor regulation in resistance artery smooth muscle. Our data indicate a high degree of isoform-selective arrestin interaction with P2Y 2 , with siRNA-mediated depletion of arrestin2 almost completely attenuating UTP-stimulated P2Y 2 -receptor desensitization.
Conversely, knockdown of arrestin3 was without effect on P2Y 2 signalling. We also assessed whether another important vasoconstrictor GPCR also differentially recruits arrestin2/3 isoforms, and showed that ET A -receptor responses are attenuated by arrestin3, but not arrestin2 knockdown. Moreover, we recently showed that GRK2 is also a critical kinase involved in ET A -receptor desensitization. 14 Consequently, our findings clearly demonstrate that phosphorylation by a common GRK isoenzyme can lead to contrasting arrestin isoform recruitment. A likely explanation that deserves future investigation is that the pattern of GRK2-mediated P2Y 2 -and ET A -receptor phosphorylation differs sufficiently to promote differential recruitment of arrestins. Finally, the potential importance of arrestin recruitment in vascular disease has been highlighted by two recent studies. Data from arrestin knockout mice reveal a role for arrestins in the regulation of vascular smooth muscle migration and proliferation during atherosclerosis and neointimal hyperplasia, 27 while arrestin3 regulates angiotensin II-stimulated, ERK-mediated aortic smooth muscle proliferation. 28 Since our new findings highlight a selective arrestin regulation of ET A -and P2Y 2 -receptors, it is likely that differential recruitment of arrestins to phosphorylated GPCRs has the potential to determine physiological and pathophysiological signalling outcomes activated by UTP and ET-1.
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